Biomarkers of type 1 diabetes (T1D) are important for assessing risk of developing disease, monitoring disease progression, and determining responses to clinical treatments. Here we review recent advances in the development of biomarkers of T1D with a focus on their utility in clinical trials.
INTRODUCTION
Preclinical and clinical evidence suggest that type 1 diabetes (T1D) is an autoimmune disease resulting from T-cell-mediated destruction of pancreatic b cells causing blood glucose dysregulation [1] . It occurs over two stages: a clinically silent period characterized by the development of insulitis, seen in animal models by immune cell infiltration of the pancreatic islets, and an overt diabetes stage, which occurs once a majority of b cells have died and blood glucose levels can no longer be regulated. Because insulitis occurs when considerable b cell mass remains, the most clinical benefit can be realized by detecting and directing therapies to this stage of disease. Additionally, differentiating those individuals at risk who will and will not progress to overt disease is essential for enrollment into preventive clinical trials.
Clinical studies with biologics -anti-CD3 mAbs, CTLA4Ig, and rituximab -have been able to modify the progression of T1D [2 && ,3-10]. However, not all drug-treated individuals respond to therapy. Identifying individuals who are most likely to respond to therapies is key because a personalized therapeutic approach will improve safety and efficacy.
Clinical trials have relied on metabolic measurements as endpoints, most commonly, C-peptide response to mixed-meal tolerance tests or clinical parameters such as HbA1c and insulin usage. However, these metabolic measurements can be affected by environmental factors including glucose control, adherence to clinical management, and physician practices. Optimally, methods that can detect the disease process itself including b cell mass, b cell death, or immune dysfunction represent important measures for assessing therapeutic effects. This represents an unmet need in the field necessary not only to select subjects for therapies but also to understand the reason why disease recurrence has been frequent in clinical trials. Goals of biomarkers in T1D clinical trials are listed below.
(1) Early detection of insulitis.
(2) Prediction of development of overt diabetes in at-risk subjects. Here we review immunologic and metabolic biomarkers in prediction of developing T1D and their utility in clinical trials (Table 1) . We also discuss the future of measuring disease-specific T cell responses and directly measuring b cell mass, insulitis, and b cell death in T1D.
aAbs IN DISEASE PREDICTION AND CLINICAL TRIALS
aAb generated towards the pancreas were first described in 1974 by Bottazzo et al. and they remain the only clinically measured sign of insulitis [11] . The initial assays, which involved detection of immunoglobulins that recognize pancreatic islet antigens, are still performed today. There are now at least five biochemically identified b cell targets recognized by autoantibodies. Those most commonly measured are aAbs to glutamic acid decarboxylase (GAD65), insulin-associated aAb (IAA), insulinoma-associated protein 2 (IA-2, previously known as ICA-512), islet-specific glucose-6-phosphatase catalytic subunit related protein (IGRP), and the most recently described zinc transporter 8 (ZnT8) [12, 13] . Insulin is the only b-cell-specific autoantigen.
aAbs are thought to develop as a result of b cell death and subsequent exposure of autoantigens to the immune system. As disease progresses, specificities to additional aAbs seem to develop sequentially, yet this process seems not to follow a specific time frame or sequence [14] . Development of additional aAbs could represent epitope spreading of the autoimmune response or even waxing and waning of antigen-specific responses.
Of the patients with recent onset T1D, diagnosed on clinical parameters, 98.2% are positive for !1 aAb, whereas 79.4% are positive for !2 aAbs [12] . The sensitivity of any single biochemical aAb ranges from 58% to 68%, but the combination of three aAbs has a sensitivity and specificity of 83% and 92%, respectively, in differentiating patients with recent onset T1D and healthy control subjects [15] . Therefore, positive aAbs are used to diagnose T1D in young patients and even older patients
KEY POINTS
Currently, clinicians and researches rely heavily on surrogates of the autoimmune process and b cell mass -autoantibodies and metabolic biomarkers -as measures of T1D; however, advancements are leading to more direct measurements of these variables.
Recent advancements are making it possible to measure diabetes antigen-specific T cells -the cells thought to be responsible for the pathogenesis of disease -in clinical trials.
New imaging techniques and biochemical assays currently being developed create the possibility to directly measure b cell mass and b cell death.
Both immune and metabolic biomarkers have been used to identify responders in recently completed clinical trials. Table 1 . Biomarkers of autoimmunity in type 1 diabetes
Measurement Description
Autoantibodies (aAbs) Detection of immunoglobulins that recognize one of five commonly measured diabetogenic antigens -GAD65, IAA, IA-2, IGRP and ZnT8 -by fluid-phase radioassay.
T cell proliferation Measurement of PBMC proliferation in response to culture with diabetogenic antigens.
Immunoblot
Measurement of PBMC proliferation in response to culture with human pancreatic islets cell antigens. Pancreatic islets are separated by electrophoresis and electroblotted onto nitrocellulose membranes for solubilization and addition to culture.
ELISPOT
Measurement of IFNg or other cytokines by PBMC in response to culture with synthetic peptides that represent naturally processed diabetogenic antigens.
Tetramer Assay
Detection by flow cytometry of diabetes antigen specific T cells by staining with fluorescently labeled diabetogenic peptide-MHC class I or II complexes. thought to have type 2 diabetes. Indeed, in the UK Prospective Diabetes Study Group (UKPDS), aAbþ individuals, who were thought to have type 2 diabetes at the time of clinical trial enrollment, had five times greater odds of requiring insulin treatment after 6 years [16] , suggesting these adult patients had autoimmune diabetes rather than the more common type 2 diabetes. In addition to being used for diagnosis, aAbs are useful in predicting disease development in at-risk relatives of patients with T1D [17, 18] . Progression of T1D differs based on which aAb is positive -specifically patients with lower levels of IAA and IA2 (but not GAD65 or ZnT8) seem to progress slower [19] . Also, early (by 9 months of age) expression of insulin aAbs identified four out of five children who progressed to diabetes by age 4 [20] .
Being positive for a single aAb can be a transient event [20] and, in addition, subjects who are positive for only a single aAb have about a 10% chance of developing disease within 5 years, even if there is a family history of T1D. The risk for diabetes increases greatly as the number of recognized different specificities increases. Individuals who are positive for three aAbs have a risk for T1D that approaches 90% within 8 years [13] . The prediction of T1D in individuals with positive aAbs depends on the population being studied. In the Diabetes Autoimmunity Study in the Young (DAISY), aAb positivity was predictive in offspring of diabetic parents who were HLA-DR3/4 DQ8. There was a high frequency of false or transiently positive tests in those who did not express these high-risk haplotypes [21] .
Collectively, these findings suggest that the number and titer of biochemical aAbs identifies individuals at high risk for disease, but their titers and positivity do not seem to be tightly correlated with disease progression. Nonetheless, although not primary effectors of b cell killing, they may have other pathologic function that may identify active disease [22] .
T CELL MARKERS IN T1D
The importance of T cells in the pathogenesis of T1D is apparent and has been highlighted in multiple clinical and laboratory studies. These studies include the finding that CD8þ T cells make up the majority of cell infiltrates in human insulitis [23] , diabetes antigen-specific CD4þ and CD8þ T cells can be found in T1D patients [24] [25] [26] [27] [28] [29] , and T cells from diabetogenic NOD mice can transfer disease to immune-deficient mice [30] . Additionally, we recently showed that diabetes antigen-reactive CD4þ T cells, isolated from patients with T1D, could cause insulitis and b cell death when they were transferred into NOD/scidgcÀ/À mice that expressed human HLA-DR4 as a transgene [31 & ]. Pathogenic T cells in patients with T1D have been identified by measuring T cell cytokine production in response to diabetes-associated antigens (enzyme-linked immunosorbent spot (ELISPOT)), T cell proliferation assays to diabetes-associated antigens or to islet proteins (immunoblot), and identification of diabetes antigen-specific T cells by class I or II MHC tetramers (Q-dots). In blinded studies, the sensitivity and specificity of the ELISPOT, T cell proliferative, and immunoblot assays for patients with T1D versus healthy control subjects were between 60-74% and 69-88%, respectively [15, 32] .
The reproducibility of antigen-specific T cell assays have been questioned [15] . However, a recent study showed the reproducibility of measuring antigen-specific T cell responses in the large multicenter TRIGR trial [33 && ]. Furthermore, the T-Cell Workshop Committee of the Immunology of Diabetes Society has published recommendations on T cell handling for analysis in clinical trials in an attempt to help improve the reproducibility of these assays [34] . The standardization of sample handling and of functional T cell assays has made considerable progress in the last 10 years. The logistics of using fresh samples for studies in clinical trial settings remain problematic, but some of the assays, e.g., Class I MHC tetramer studies, can be performed with frozen samples, which is important for their use in trials.
In clinical trials, population measurements of polyclonal T cells have distinguished responders to treatments. After treatment with teplizumab, clinical responders showed an increase in CD8þ central memory cells [4] whereas responders to alefacept (soluble LFA3) showed a reduced frequency of effector T cells and an increase in the ratio of Treg/ Teff [35 && ]. Surprising results have also emerged from studies of antigen-specific T cells. In the rituximab trial of patients with new onset T1D, the T cell proliferation response to diabetes-associated isletspecific and neuronal antigens increased over 12 months in responders, but did not change in the nonresponders [36] .
Class I MHC tetramers have been used to study the frequency of autoantigen-specific T cells in patients with reactivation of autoimmunity following islet cell transplant [37] and to track the effects after immune therapy with anti-CD3 mAb [24, 38] . In the latter, the frequency of GAD65 and insulin B chain peptide reactive T cells increased following treatment with anti-CD3 mAb.
There are a number of potential explanations for study results that have shown either no change or even increased frequency and proliferation of antigen-reactive T cells with successful immune therapy. One is that the frequency of the cells in the peripheral blood does not reflect what has occurred in the pancreas, but may even reflect egress of the antigen-specific cells from the pathologic site or other sites, such as the gut following therapy. We and others have shown that anti-CD3 mAb can cause the migration of T cells to the gastrointestinal tract where they acquire regulatory function [39, 40] .
b CELLULAR BIOMARKERS
Though b cells are the focus of the autoimmune attack in T1D, our ability to directly measure b cell mass, death, and even insulin secretion is currently limited. The difficult anatomical location of the pancreas and that b cells make up only 2-3% of pancreatic tissue have made it challenging to establish biopsy and imaging techniques to directly study b cells in vivo.
Currently, development of new techniques to measure b cell mass and inflammation is underway. In NOD mice, researchers have been able to magnetically label diabetogenic T cells and image their recruitment to the pancreas in real time [41] . Additionally, in humans, magnetic nanoparticles have been used to visualize pancreatic inflammation in T1D by exploiting vessel leakiness for extravasation of the nanoparticles into inflammatory tissues [42] .
Other studies have used MRI, PET, and singlephoton emission computed tomography (SPECT) to directly image pancreatic b cells. b cells express the vesicular monoamine transporter (VMAT), which can be identified with 18F-fluoropropyl-dihydrotetrabenazine (18F-DTBZ) [43] [44] [45] . There is some uncertainty about the specificity of the expression of VMAT on pancreatic b cells as a signal in the exocrine pancreas has been noted by some investigators in rodents [46] . In humans, ongoing studies are evaluating background staining with 18F-DTBZ to clarify this question. Clearly, the utility of the method will depend on its sensitivity and the variability in measurement because the average loss of C-peptide at the end of the first year of T1D in contemporary studies was modest: À0.017 pmol/mL/month or approximately 29% of the baseline [47] .
The end points commonly used in clinical trials measure provoked C-peptide responses and do not directly measure b cell death, yet reducing b cell death is the treatment objective of therapeutics. We recently developed an assay to measure b cell death by detection of the levels of b-cell-derived INS DNA [48] . INS DNA derived from b cells has unmethylated CpG sites that enable gene transcription. The levels of unmethylated INS DNA are increased in patients with recent onset T1D and (in unpublished studies) are increased in individuals at risk for the disease who progress to T1D. We found that there was a decrease in the levels of unmethylated INS DNA in patients who were treated with teplizumab suggesting that drug treatment decreased the rate of b cell death [49 && ]. Additionally, in preclinical models of T1D, a microRNA expressed in large amounts in b cells, has been shown to be elevated in the blood after b cell death: a finding that remains to be validated in humans [50 & ].
Biomarkers for prediction of clinical responses to interventions
The utility of aAb measurements as biomarkers of response to immune therapy is not established. Improvements in metabolic outcomes with anti-CD3 mAbs were not associated with significant changes in aAb titers [3, 5] . Conversely, anti-CD20 mAb treatment which targets B cell subsets, but not plasma cells, improved b cell function over the first year of disease and significantly decreased IAA titers in 40% of drug-treated patients compared to 0% of placebo [51] . In the Oral Insulin DPT-1 trial, subjects with the highest titers of insulin aAbs showed the most significant protection from T1D [52] . Conversely, in GAD65/alum trials, immunization resulted in an increase in the titer of anti-GAD65 aAbs, and also altered cytokine responses to GAD65, but there was not a significant effect of the treatment on C-peptide responses [53,54 & ]. Not all individuals with new onset T1D respond equally to intervention. In a recent teplizumab trial, 45% of drug-treated individuals showed robust responses -with an average C-peptide loss of less than 10% after 2 years, whereas 55%, the 'nonresponders', showed a decline in C-peptide that was similar to untreated subjects [2 && ].
In our recent study of teplizumab, there were differences in the T cell phenotypes, before drug treatment in clinical responders and nonresponders. Specifically, clinical responders showed an increased frequency of CD8þ effector memory T cells and terminally differentiated CD8þ effector T cells and a lower frequency of IFNgþ CD8þ, subpopulations of naive CD4þ and CD8þ and CCR4þ memory CD4þ T cells [2 && ]. Unexpectedly, metabolic features also distinguished responders and nonresponders to drug treatment. Clinical responders had lower HbA1c levels and insulin use at the time of study entry compared to nonresponders. These differences were not explained by the levels of stimulated C-peptide, which were not different in the responders and nonresponders at the time of study entry. Likewise, in the TrialNet abatacept study, HbA1c less than 6.0% tended to have better responses compared to those with higher levels [8] .
Other nonimmunologic parameters have also been found to predict clinical responses. In the Protégé and Delay trials of teplizumab, clinical responders were younger and had shorter disease durations than nonresponders [4, 10] . The responses to rituximab also tended to be better in younger subjects [9] . Thus, in addition to immunologic differences, it is important to consider differences in other disease relevant measures.
Even among subjects who were treated with agents that did not show efficacy overall, there may be subgroups for whom interventions are effective. These observations are not surprising as there are genetic polymorphisms and acquired differences between individuals that may modify drug response, and not all forms of the disease may have the same cause or respond to therapy in the same manner. Identification of individuals likely to respond to a specific therapy represents a valuable tool for improving the efficiency and equipoise of clinical trials.
CONCLUSION
While there have been advances in the development of immunologic measurements, the relationships between these parameters and metabolic progression of disease and therapy responses are still under investigation, and a single test cannot substitute for the measurement of C-peptide responses. Detection of biochemical aAbs remains the most reproducible and predictive measurement to identify individuals at high risk for the disease, but does not provide information about the process in real time. Cellular biomarkers have been widely used, but there is limited information on how changes in cell subsets can predict immune therapy responses.
The heterogeneity in responses to immune interventions highlights the importance in identifying biomarkers that can identify individuals most likely to respond to a given intervention. To date, the most reliable parameters have been metabolic and demographic, but further immune studies may refine our ability to match interventions with patients.
